Clinical Trials Logo

Retinal Disease clinical trials

View clinical trials related to Retinal Disease.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06394232 Recruiting - Clinical trials for Age-Related Macular Degeneration

Safety & Efficacy of Eyecyte-RPEā„¢ in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration.

Start date: June 4, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this clinical study is to evaluate the safety and efficacy of novel stem cell formulation in patients having Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (d-AMD). The main questions it aims to answer are: - Safety and tolerability of the novel stem cell formulation - Potential efficacy of the novel stem cell formulation Participants will receive a single subretinal injection in their study eye and followed up for safety. This is an India only study and the product is developed indigenously.

NCT ID: NCT06305416 Recruiting - Clinical trials for Diabetic Retinopathy

A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema

Start date: March 30, 2024
Phase: Phase 3
Study type: Interventional

Macular edema in diabetes, defined as retinal thickening within two disc diameters of the center of the macula, results from retinal microvascular changes that compromise the blood-retinal barrier, causing leakage of plasma constituents into the surrounding retina and consequently retinal edema. Thickening of the basement membrane and reduction in the number of pericytes are believed to lead to increased permeability and incompetence of the retinal vasculature. This compromise of the blood-retinal barrier leads to the leakage of plasma constituents into the surrounding retina with subsequent retinal edema. Hypoxia produced by this mechanism can also stimulate the production of vascular endothelial growth factor (VEGF). Vascular endothelial growth factor (VEGF) increases retinal vascular permeability, causes breakdown of the blood-retina barrier and results in retinal edema. Diabetic macular edema (DME) is the most common cause of visual reduction in patients with Diabetes Mellitus. The prevalence of DME globally is around 6.8 %. Diabetic Retinopathy (DR) is the most common microvascular complication of diabetes and the leading cause of blindness worldwide. DME is a complication of diabetic retinopathy that affects the macula, which is located at the center of the retina and responsible for central vision. Bangladesh is the 10th country in the world for the number of adults living with diabetes with some 7.1 million (5.3-12.0). In Bangladesh, it is therefore expected that diabetic secondary complications, like DR, will increase along with the rising trend of diabetes mellitus. The use of therapeutic monoclonal antibodies has revolutionized in the treatment of many diseases. In recent years, millions of patients have been successfully treated with these biological agents. Ranibizumab is one such therapeutic monoclonal antibody for intraocular use. Ranibizumab is a humanized, recombinant, immunoglobulin G1 monoclonal antibody fragment against vascular endothelial growth factor A (VEGF-A) and thus prevents choroidal neovascularization. The small size of ranibizumab allows for enhanced diffusion into the retina and choroid.

NCT ID: NCT06289452 Recruiting - Eye Diseases Clinical Trials

Safety and Efficacy Study of IVB102 Injection in Subjects With X-linked Retinoschisis

Start date: March 8, 2024
Phase: Early Phase 1
Study type: Interventional

The goal of this clinical trial is to evaluate the safety and efficacy of IVB102 injection in subjects with XLRS.

NCT ID: NCT06287645 Recruiting - Clinical trials for Diabetic Retinopathy

Color Fundus Photograph With Experts Labelling

Start date: May 12, 2022
Phase:
Study type: Observational [Patient Registry]

This trial aims to provide a digital retinal image dataset from Pakistan, graded by three specialists according to the severity of Diabetic Retinopathy. The dataset aims to improve research and patient care.

NCT ID: NCT06269666 Recruiting - Retinal Disease Clinical Trials

P200TxE Diseased Eye Image Collection

Start date: January 31, 2024
Phase: N/A
Study type: Interventional

The primary objective is to collect images on the P200TxE device in diseased eyes.

NCT ID: NCT06139523 Recruiting - Glaucoma Clinical Trials

Optimize Pediatric OCT Imaging

Start date: January 24, 2024
Phase:
Study type: Observational

Handheld optical coherence tomography (OCT) has become an important imaging modality to evaluate the pediatric retina. The objective of this pilot study is to compare a new contact OCT system (Theia Imaging) with an investigational noncontact OCT system (Duke Biomedical Engineering) to assess their ability to image the pediatric retina. The investigators hypothesize that the contact OCT system is superior in imaging larger areas of the retina (larger field-of-view), while it has similar resolution to image the retina substructures (non-inferior image quality).

NCT ID: NCT06074731 Recruiting - Clinical trials for Diabetic Retinopathy

Diagnostic Possibilities in Ophthalmological Diseases Using Swept Source Optical Coherence Tomography

Start date: June 1, 2017
Phase:
Study type: Observational

In this pilot study we want to investigate morphological features acquired by the novel image modality and gain information regarding disease pathomechanism, development and future possible influence on disease management for patients affected by those diseases.

NCT ID: NCT06011798 Recruiting - Diabetes Mellitus Clinical Trials

Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE)

Start date: August 23, 2023
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to assess the efficacy and safety of multiple doses of foselutoclax (UBX1325) in patients with Diabetic Macular Edema. The main questions the study aims to answer are: - Assess the efficacy of foselutoclax compared to aflibercept - Assess the safety and tolerability of foselutoclax

NCT ID: NCT05981950 Recruiting - Clinical trials for Artificial Intelligence

Real-world of AI in Diagnosing Retinal Diseases

Start date: August 1, 2023
Phase:
Study type: Observational

The objective of this study is to apply an artificial intelligence algorithm to diagnose multi-retinal diseases in real-world settings. The effectiveness and accuracy of this algorithm are evaluated by sensitivity, specificity, positive predictive value, negative predictive value, and area under curve.

NCT ID: NCT05958927 Recruiting - Oxidative Stress Clinical Trials

Fundus Findings and Thiol-Disulfide Homeostais

Start date: April 13, 2023
Phase:
Study type: Observational

Gestational diabetes mellitus is associated with abnormal blood sugar levels throughout pregnancy in women without prior diabetes. Many studies have been conducted on the relationship between diabetes and oxidative stress. In this study, it was aimed to investigate the presence of fundus findings in patients with gestational diabetes and/or impaired blood sugar based on the results of previous studies and to simultaneously investigate the thiol-disulfide homeostasis in the tears of the patients.There was no previous study in the literature on thiol disulfide homeostasis in tears in gestational diabetic patients.